ClinVar Miner

Submissions for variant NM_005251.3(FOXC2):c.361C>T (p.Arg121Cys) (rs1567571184)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
The Molecular Genetic Diagnosis Center, Children’s Hospital of Fudan University RCV000735835 SCV001190559 pathogenic Distichiasis-lymphedema syndrome 2019-05-10 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV001289872 SCV001477871 likely pathogenic none provided 2020-02-18 criteria provided, single submitter clinical testing The FOXC2 c.361C>T; p.Arg121Cys variant is reported in the literature in several individuals affected with primary lymphedema (Lyons 2017, Sargent 2014, van Steensel 2009). This variant was found to segregate with disease in several members of a family with hereditary lymphedema (Sargent 2014). This variant is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. The arginine at codon 121 is highly conserved, and it occurs in the forkhead DNA-binding domain and interacts with bases in the DNA major groove (Li 2019). Functional assays show that the p.Arg121Cys variant lacks measurable transcriptional activation activity in cultured cells (van Steensel 2009). Additionally, another amino acid substitution at this codon (p.Arg121His) has been reported in an individual with hereditary lymphedema and lacks DNA-binding and transcriptional activation activity (Berry 2005). Based on available information, the p.Arg121Cys variant is considered to be likely pathogenic. References: Berry FB et al. The establishment of a predictive mutational model of the forkhead domain through the analyses of FOXC2 missense mutations identified in patients with hereditary lymphedema with distichiasis. Hum Mol Genet. 2005 Sep 15;14(18):2619-27. Li S et al. Crystal Structure of FOXC2 in Complex with DNA Target. ACS Omega. 2019 Jun 24;4(6):10906-10914. Lyons O et al. Human venous valve disease caused by mutations in FOXC2 and GJC2. J Exp Med. 2017 Jul 19. pii: jem.20160875. Sargent C et al. A five generation family with a novel mutation in FOXC2 and lymphedema worsening to hydrops in the youngest generation. Am J Med Genet A. 2014 Nov;164A(11):2802-7. van Steensel MA et al. Novel missense mutations in the FOXC2 gene alter transcriptional activity. Hum Mutat. 2009 Dec;30(12):E1002-9.
OMIM RCV000735835 SCV000863987 pathogenic Distichiasis-lymphedema syndrome 2019-01-02 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.